Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Clin Virol ; 129: 104453, 2020 08.
Article in English | MEDLINE | ID: mdl-32534437

ABSTRACT

BACKGROUND: Since its first isolation in 2005, Human Bocavirus (HBoV) has been repeatedly associated with acute respiratory tract infections, although its role in pathogenicity remains unclear due to high co-infection rates. OBJECTIVES: To assess HBoV prevalence and associated disease in a cohort of respiratory patients in the East Midlands, UK between 2015 and 2019. STUDY DESIGN: We initially investigated the undiagnosed burden of HBoV in a retrospective paediatric cohort sampled between 2015 and 2017 using an in-house PCR assay. HBoV was subsequently incorporated into the standard respiratory diagnostic pathway and we audited a calendar year of HBoV positive results between 2018 and 2019. RESULTS: Our retrospective PCR screening of previously routine diagnostic-negative samples from juvenile patients identified a 9% (n = 30) prevalence of HBoV type 1. These apparent HBoV1 mono-infections were frequently associated with respiratory tract symptoms, often severe requiring ventilation, oxygen and steroid intervention with 31% (n = 9) of individuals requiring intensive care. When HBoV screening was subsequently adopted into the routine respiratory diagnostic pathway, year-round infections were observed in both children and adults peaking in February. 185 of 9098 (2.03%) individuals were found to be HBoV positive with children aged 12-24 months the principally infected group. However, HBoV infection was also observed in patients aged over 60, predominantly as a mono-infection. 23% of the 185 unique patients were HBoV monoinfected and persistent low-level DNA positivity was observed in 15 individuals up to 6-months after initial presentation. CONCLUSION: HBoV1 is a prevalent respiratory infection in the UK capable of causing serious monoinfections.


Subject(s)
Human bocavirus , Parvoviridae Infections , Respiratory Tract Infections , Adult , Child , Escherichia coli , Humans , Infant , Retrospective Studies , United Kingdom
2.
Arch Dis Child ; 102(4): 366-370, 2017 04.
Article in English | MEDLINE | ID: mdl-27765754

ABSTRACT

Children with shunts commonly present with fever, and often the focus of infection will be unrelated to their shunt. However, as shunt infections may present with few or even no specific symptoms, evaluation of a child with a shunt presenting with fever should be careful and comprehensive to ensure shunt infections are not missed. Treatment of an infected shunt involves removal of the shunt followed by a long course of antibiotics; missing or partially treating shunt infections can result in significant morbidity and potentially even mortality. Our experience of managing children with shunts presenting with fever is that many non-specialist clinicians have little experience in this area so initial management may not always be appropriate. Those children who are most at risk of shunt infection are those who within the preceding 8 weeks have had insertion, revision or access of their shunt or chemotherapy device, or have had abdominal surgery in the presence of a ventriculoperitoneal shunt. We have chosen 8 weeks as a pragmatic time point, as in our experience the vast majority of children who have had shunt infections have presented within this period. The caveat is that this should not be used as an absolute cut-off where there is strong suspicion of shunt infection or no clear focus at a later time point.


Subject(s)
Cerebrospinal Fluid Shunts , Fever/therapy , Anti-Bacterial Agents/therapeutic use , Equipment Contamination , Fever/etiology , Humans , Neuroimaging , Patient Discharge Summaries , Surgical Wound Infection/diagnosis , Surgical Wound Infection/etiology , Tomography, X-Ray Computed
3.
Pediatrics ; 138(5)2016 11.
Article in English | MEDLINE | ID: mdl-27940783

ABSTRACT

BACKGROUND AND OBJECTIVE: Neonatal respiratory disease, particularly bronchopulmonary dysplasia, remains one of the leading causes of morbidity and mortality in newborn infants. Recent evidence suggests nosocomially acquired viral respiratory tract infections (VRTIs) are not uncommon in the NICU. The goal of this study was to assess the association between nosocomial VRTIs, neonatal respiratory disease, and the health care related costs. METHODS: A matched case-control study was conducted in 2 tertiary NICUs during a 6-year period in Nottingham, United Kingdom. Case subjects were symptomatic neonatal patients with a confirmed real-time polymerase chain reaction diagnosis of a VRTI. Matched controls had never tested positive for a VRTI. Multivariable logistic regression was used to test for associations with key respiratory outcomes. RESULTS: There were 7995 admissions during the study period, with 92 case subjects matched to 183 control subjects. Baseline characteristics were similar, with a median gestation of 29 weeks. Rhinovirus was found in 74% of VRTIs. During VRTIs, 51% of infants needed escalation of respiratory support, and case subjects required significantly more respiratory pressure support overall (25 vs 7 days; P < .001). Case subjects spent longer in the hospital (76 vs 41 days; P < .001), twice as many required home oxygen (37%; odds ratio: 3.94 [95% confidence interval: 1.92-8.06]; P < .001), and in-hospital care costs were significantly higher (£49 664 [$71 861] vs £22 155 [$32 057]; P < .001). CONCLUSIONS: Nosocomial VRTIs in neonatal patients are associated with significant greater respiratory morbidity and health care costs. Prevention efforts must be explored.


Subject(s)
Cross Infection/mortality , Hospital Mortality/trends , Infant, Premature , Respiratory Tract Infections/mortality , Respiratory Tract Infections/virology , Case-Control Studies , Combined Modality Therapy , Critical Care/methods , Cross Infection/physiopathology , Cross Infection/virology , Female , Follow-Up Studies , Gestational Age , Humans , Infant, Newborn , Intensive Care Units, Neonatal , Length of Stay , Male , Respiratory Tract Infections/therapy , Retrospective Studies , Risk Assessment , Severity of Illness Index , Survival Analysis , Tertiary Care Centers , United Kingdom
4.
BMJ Case Rep ; 20122012 May 08.
Article in English | MEDLINE | ID: mdl-22605835

ABSTRACT

The patient presented with increasing fatigue and dyspnoea. The patient had medical history of rheumatoid arthritis for which she had been taking methotrexate for the past 15 years and etanercept for the past 6 years. Initial diagnosis was cardiac failure but further investigation by echocardiogram revealed a large pericardial effusion. Empirical piperacillin-tazobactam was started due to moderately raised inflammatory markers. Four hundred millilitre of frank pus was aspirated from the pericardial sac and antimicrobial treatment was changed to meropenem. Gram positive cocci were seen in the initial Gram stain, but conventional cultures remained negative. However, 16S ribosomal RNA gene sequencing of the pus sample detected the presence of Parvimonas micra genome. Reaccumulation of the effusion required further drainage where again P micra was detected by 16S ribosomal RNA gene sequencing. Two weeks of meropenem was completed followed by treatment with benzylpenicillin and metronidazole.


Subject(s)
Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Immunoglobulin G/adverse effects , Opportunistic Infections/diagnosis , Opportunistic Infections/drug therapy , Opportunistic Infections/microbiology , Pericarditis/diagnosis , Pericarditis/drug therapy , Pericarditis/microbiology , Aged , Anti-Bacterial Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Drug Therapy, Combination , Etanercept , Female , Gram-Positive Bacteria/isolation & purification , Humans , Immunoglobulin G/therapeutic use , Meropenem , Metronidazole/therapeutic use , Penicillin G/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Risk Factors , Thienamycins/therapeutic use
5.
Ann Clin Microbiol Antimicrob ; 10: 17, 2011 May 12.
Article in English | MEDLINE | ID: mdl-21569379

ABSTRACT

Arcanobacterium haemolyticum is an organism that commonly causes pharyngitis and wound infections. It does not usually cause systemic invasive disease. The organism presents a difficult diagnostic problem because the Clinical Microbiology laboratory has a propensity to view them as diphtheroid organisms of the Corynebacterium species, thus contaminants or normal flora. We describe a case of a 21-year-old female who had endocarditis with cerebral emboli due to Arcanobacterium haemolyticum. This rare condition is associated with significant mortality and to the best of our knowledge; this is the first successfully treated case of A. haemolyticum endocarditis complicated by embolic phenomenon.


Subject(s)
Actinomycetales Infections/microbiology , Arcanobacterium/isolation & purification , Endocarditis, Bacterial/microbiology , Actinomycetales Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Arcanobacterium/drug effects , Female , Humans , Young Adult
6.
Diabetes Care ; 33(12): 2514-20, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21115765

ABSTRACT

OBJECTIVE: To implement and evaluate a regional prepregnancy care program in women with type 1 and type 2 diabetes. RESEARCH DESIGN AND METHODS: Prepregnancy care was promoted among patients and health professionals and delivered across 10 regional maternity units. A prospective cohort study of 680 pregnancies in women with type 1 and type 2 diabetes was performed. Primary outcomes were adverse pregnancy outcome (congenital malformation, stillbirth, or neonatal death), congenital malformation, and indicators of pregnancy preparation (5 mg folic acid, gestational age, and A1C). Comparisons were made with a historical cohort (n = 613 pregnancies) from the same units during 1999-2004. RESULTS: A total of 181 (27%) women attended, and 499 women (73%) did not attend prepregnancy care. Women with prepregnancy care presented earlier (6.7 vs. 7.7 weeks; P < 0.001), were more likely to take 5 mg preconception folic acid (88.2 vs. 26.7%; P < 0.0001) and had lower A1C levels (A1C 6.9 vs. 7.6%; P < 0.0001). They had fewer adverse pregnancy outcomes (1.3 vs. 7.8%; P = 0.009). Multivariate logistic regression confirmed that in addition to glycemic control, lack of prepregnancy care was independently associated with adverse outcome (odds ratio 0.2 [95% CI 0.05-0.89]; P = 0.03). Compared with 1999-2004, folic acid supplementation increased (40.7 vs. 32.5%; P = 0.006) and congenital malformations decreased (4.3 vs. 7.3%; P = 0.04). CONCLUSIONS: Regional prepregnancy care was associated with improved pregnancy preparation and reduced risk of adverse pregnancy outcome in type 1 and type 2 diabetes. Prepregnancy care had benefits beyond improved glycemic control and was a stronger predictor of pregnancy outcome than maternal obesity, ethnicity, or social disadvantage.


Subject(s)
Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 2/blood , Prenatal Care/statistics & numerical data , Adult , Blood Glucose/metabolism , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Female , Humans , Pregnancy , Pregnancy Outcome , Pregnancy in Diabetics/blood , Pregnancy in Diabetics/physiopathology , Risk Factors , Young Adult
7.
J Infect ; 54(3): e129-31, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17027086

ABSTRACT

We describe an 80-year-old lady with a meningoencephalitic illness followed by vertebral discitis. Enterococcus avium was cultured from her cerebrospinal fluid. No other pathogen was incriminated in her illness. The meningoencephalitic illness settled after 3 weeks of antimicrobials, but the vertebral discitis required longer therapy.


Subject(s)
Discitis/microbiology , Enterococcus/isolation & purification , Gram-Positive Bacterial Infections/microbiology , Meningoencephalitis/complications , Meningoencephalitis/microbiology , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Cerebrospinal Fluid/microbiology , Discitis/drug therapy , Female , Humans , Meningoencephalitis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...